Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aa retrospective study of comparative effectiveness and safety of rivaroxaban and warfarin among Nonvalvular Atrial Fibrillation (NVAF) patients with obesity and polypharmacy in the USA

Next Previous
X
Search
Trial Profile

Aa retrospective study of comparative effectiveness and safety of rivaroxaban and warfarin among Nonvalvular Atrial Fibrillation (NVAF) patients with obesity and polypharmacy in the USA

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Cardiovascular disorders; Stroke; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 29 Jan 2022 Results published in the American Journal of Cardiovascular Drugs
    • 31 May 2021 New trial record
    • 25 May 2021 Results published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top